This Article Full Text Full Text (PDF) CME: Take the course for this article: Anaplastic Large Cell Lymphoma, T-/Null-Cell Type eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Jacobsen, E. Search for Related Content PubMed Articles by Jacobsen, E.

Lymphoma Series: Variants of Large-Cell Lymphoma

Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type

Harvard Medical School, Lymphoma Program, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Key Words. Anaplastic large cell plymphoma • Lymphomatoid papulosis • Cutaneous lymphoma • ALK

Correspondence: Eric Jacobsen, M.D., Dana-Farber Cancer Institute, Dana 1B30, 44 Binney Street, Boston, Massachusetts 02115, USA. Telephone: 617-632-6633; Fax: 617-632-5168; e-mail: Eric_Jacobsen{at}dfci.harvard.edu

Anaplastic large-cell lymphoma, T-/null-cell type (ALCL), is a rare disease that has only been well characterized for two decades. Despite this, the biology of ALCL is better understood than that of many other more common variants of lymphoma. This review focuses on the pathophysiology, clinical presentation, and therapy of ALCL, including stem cell transplantation. In particular, the text emphasizes how novel prognostic features and the evolving understanding of the biology of this disease will influence treatment selection and drug development.